Shiuh Cheng, MD
Nephrology · Honolulu, HINPI 1962493049
Payments from drug & device makers
Across 491 payments — averaging $42.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Calliditas Therapeutics US Inc.$3K
- AstraZeneca$3K
- Amgen$2K
- Vantive US Healthcare LLC$2K
- Bayer$2K
- Aurinia Pharma U.S., Inc.$999
- plus $8K from 29 others
What the payments were for
- Consulting fees$1,6008%
- Travel & lodging$1,7758%
- Food & beverage$17,41383%
- Education$2921%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Calliditas Therapeutics US Inc. | 44 | $3,344 |
| AstraZeneca(2 entities) | 67 | $2,692 |
| Amgen(2 entities) | 61 | $2,254 |
| Vantive US Healthcare LLC | 13 | $2,196 |
| Bayer | 67 | $1,837 |
| Aurinia Pharma U.S., Inc. | 32 | $999 |
| Travere Therapeutics, Inc. | 18 | $703 |
| ANI Pharmaceuticals, Inc. | 29 | $650 |
| Novo Nordisk | 11 | $560 |
| Otsuka America Pharmaceutical, Inc. | 15 | $530 |
| Baxter Healthcare | 6 | $472 |
| Vifor Pharma, Inc. | 20 | $458 |
| Boehringer Ingelheim | 11 | $452 |
| GSK | 11 | $449 |
| Nxstage Medical, Inc. | 5 | $436 |
| Mallinckrodt Hospital Products Inc. | 14 | $394 |
| Ardelyx, Inc. | 21 | $377 |
| Akebia Therapeutics Inc | 7 | $360 |
| Apellis Pharmaceuticals, Inc. | 2 | $250 |
| Sanofi-aventis U.S. LLC | 2 | $237 |
| Sanofi | 2 | $179 |
| Kyowa Kirin, Inc. | 4 | $174 |
| Amarin Pharma, Inc. | 4 | $157 |
| AbbVie(2 entities) | 6 | $142 |
| Sanofi US Services Inc. | 1 | $139 |
| Novartis | 4 | $133 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $114 |
| Mallinckrodt Enterprises LLC | 2 | $103 |
| Veloxis Pharmaceuticals, Inc. | 3 | $102 |
| Alnylam Pharmaceuticals Inc. | 3 | $77 |
| Dexcom, Inc. | 1 | $27 |
| Amicus Therapeutics, Inc. | 1 | $26 |
| Genentech USA, Inc. | 1 | $23 |
| Exact Sciences | 1 | $21 |
| Scpharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TARPEYO$2,503
- Renal - Chronic$1,896
- Kerendia$1,047
- Tavneos$905
- FARXIGA$482
- LOKELMA$480
- LUPKYNIS$399
- NXSTAGE SYSTEM ONE$382
- JYNARQUE$364
- KRYSTEXXA$287
- Filspari$278
- Vafseo$253
- Empaveli$250
- JARDIANCE$244
- BENLYSTA$240
- THYMOGLOBULIN$237
- Renal - Acute$235
- Renal - PD$230
- PURIFIED CORTROPHIN GEL$132
- CRYSVITA$125
How this compares
$21,080 in reported general payments places this provider in the 85th percentile of 57 nephrology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 282 | $317,395 |
| VelphoroSucroferric Oxyhydroxide | 56 | $136,340 |
| KerendiaFinerenone | 101 | $123,254 |
| VeltassaPatiromer Calcium Sorbitex | 42 | $75,965 |
| LokelmaSodium Zirconium Cyclosilicate | 48 | $69,145 |
| JardianceEmpagliflozin | 49 | $53,300 |
| AuryxiaFerric Citrate | 13 | $38,098 |
| Cinacalcet Hcl | 21 | $29,549 |
| JanuviaSitagliptin Phosphate | 22 | $22,402 |
| Sevelamer Carbonate | 83 | $20,765 |
| Calcium Acetate | 100 | $9,710 |
| DapagliflozinDapagliflozin Propanediol | 14 | $6,828 |
| VascepaIcosapent Ethyl | 11 | $6,093 |
| Losartan Potassium | 249 | $2,777 |
| Tacrolimus | 15 | $1,490 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $2,692 | $386,541330 claims |
| BayerKerendia | $1,837 | $123,254101 claims |
| Boehringer IngelheimJardiance | $452 | $53,30049 claims |
| Akebia Therapeutics IncAuryxia | $360 | $38,09813 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $650 | $26412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 57 nephrology providers in Hawaii.
Other nephrology in Honolulu
- Kunal ParekhHonolulu$172K
- Christie IzutsuHonolulu$50K
- Jared SugiharaHonolulu$39K
- Eugene WongHonolulu$37K
- Leilani Ka'aneheHonolulu$10K
- Antonette Veronica HernandezHonolulu$9K
- Rick HayashiHonolulu$5K
- David NaaiHonolulu$5K
- Arie Olivo GanzHonolulu$5K
- Sorkko ThirunavukkarasuHonolulu$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.